局限性前列腺癌选择性淋巴结放疗:一项荟萃分析
该荟萃分析纳入4项随机试验共4465例局限性前列腺癌患者,比较全盆腔放疗(WPRT)与前列腺-only放疗。结果显示WPRT未显著改善总生存、生化复发或远处转移,异质性主要源于POP-RT试验。
要点
- WPRT未改善总生存(HR 1.05,95%CI 0.95-1.16)。
- WPRT未显著改善生化复发(HR 0.82,95%CI 0.63-1.07)。
- WPRT未显著改善远处转移(HR 0.88,95%CI 0.58-1.34)。
核心结论
- 在未选择的局限性前列腺癌患者中,全盆腔放疗较前列腺-only放疗未显示有意义的获益。
研究设计与样本
- 聚合荟萃分析,系统检索PubMed via MEDLINE、clinicaltrials.gov和会议论文集,纳入1980至2025年间发表的±WPRT随机试验。
- 共纳入4项随机试验(n=4465),包括GETUG-AFU-01、RTOG 9413、RTOG 0924和POP-RT。
- 采用随机效应模型生成合并风险比(HR)及95%CI,用I2评估异质性,并行留一法敏感性分析和荟萃回归。
主要发现
- WPRT未改善总生存(HR 1.05;95%CI 0.95-1.16;I2=0%)。
- WPRT未改善生化复发(HR 0.82;95%CI 0.63-1.07;I2=76%)。
- WPRT未改善远处转移(HR 0.88;95%CI 0.58-1.34;I2=68%)。
- 高异质性主要源于POP-RT试验;排除POP-RT后异质性消除(生化复发HR 0.91 [95%CI 0.81-1.02;I2=0%];远处转移HR 1.06 [95%CI 0.87-1.29;I2=0%])。
- 荟萃回归未发现所评估协变量(Gleason评分7-10比例、雄激素剥夺治疗使用、放疗剂量、照射野大小)有显著修饰效应。
关键数值与推荐
- WPRT对比前列腺-only放疗的总生存合并HR为1.05(95%CI 0.95-1.16;I2=0%)。
- WPRT对比前列腺-only放疗的生化复发合并HR为0.82(95%CI 0.63-1.07;I2=76%)。
- WPRT对比前列腺-only放疗的远处转移合并HR为0.88(95%CI 0.58-1.34;I2=68%)。
- 排除POP-RT后,生化复发HR为0.91(95%CI 0.81-1.02;I2=0%),远处转移HR为1.06(95%CI 0.87-1.29;I2=0%)。
临床怎么用
- 在未选择的局限性前列腺癌患者中,不支持常规使用全盆腔放疗替代前列腺-only放疗。
- 对可能获益的特定亚组,需等待个体患者数据荟萃分析进一步明确。
局限性
- 纳入试验数量少(4项),其中1项为单中心试验(POP-RT),对异质性影响大。
- 为聚合数据荟萃分析,无法评估个体患者水平的亚组获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recently, results from National Surgical Adjuvant Breast and Bowel Project; Radiation Therapy Oncology Group; Gynecologic Oncologic Group (NRG/RTOG) 0924, the largest randomized trial to evaluate the benefit of whole-pelvic radiation therapy (WPRT) in localized prostate cancer, were presented. We conducted an aggregate meta-analysis of all phase III randomized trials to determine the impact of WPRT on oncologic outcomes. METHODS: PubMed via MEDLINE, clinicaltrials.gov, and conference proceedings were systematically searched for randomized trials of ±WPRT in localized prostate cancer conducted between 1980 and 2025. Random-effects models were used to generate pooled hazard ratios (HRs) with 95% CIs. Heterogeneity was assessed with I2 statistics, and leave-one-out sensitivity analyses were performed. Meta-regression was performed to assess the influence of the proportion of patients with Gleason score 7 to 10, use of androgen deprivation therapy, radiation therapy dose, and field size. Endpoints assessed included overall survival, a biochemical-based endpoint, referred to as biochemical recurrence, and distant metastasis. RESULTS: Four randomized trials were identified (n = 4465 patients), including 3 multicenter cooperative group trials Urogenital Tumor Study Group-French Association of Urology (GETUG-AFU-01, RTOG 9413, and RTOG 0924) and 1 single-institution trial Prostate-Only versus Whole-Pelvic Radiation Therapy (POP-RT). WPRT did not improve overall survival (HR, 1.05; 95% CI, 0.95-1.16; I2 = 0%), biochemical recurrence (HR, 0.82; 95% CI, 0.63-1.07; I2 = 76%), or distant metastasis (HR, 0.88; 95% CI, 0.58-1.34; I2 = 68%). The high rates of heterogeneity observed were due primarily to the POP-RT trial. In sensitivity analyses, excluding POP-RT heterogeneity was eliminated (HR for biochemical recurrence was 0.91 [95% CI, 0.81-1.02; I2 = 0%]; HR for distant metastasis was 1.06 [95% CI, 0.87-1.29; I2 = 0%]). Meta-regression found no significant modifying effect of any covariables assessed. CONCLUSIONS: This aggregate meta-analysis did not demonstrate any meaningful benefit of WPRT over prostate-only radiation therapy in unselected localized prostate cancer. Individual patient data meta-analysis is warranted to understand whether any subgroup consistently derives benefit from WPRT.
引用
- Roy S, Jia AY, Zaorsky NG, et al. Elective Nodal Radiation Therapy in Localized Prostate Cancer: A Meta-Analysis. Int J Radiat Oncol Biol Phys. 2026. PMID: 42176865. doi:10.1016/j.ijrobp.2026.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。